Merck Stock Revenue Growth Masks Loss and Margin Compression

Merck's (MRK) stock remained relatively unchanged after its latest earnings report, despite showing solid revenue growth. The company's Q2 2026 earnings showed a revenue of $16.6 billion, up about 5% from the previous year. However, earnings took a hit due to a multi-billion dollar acquisition charge, which pushed basic earnings per share into a loss.

The loss of $1.3 billion is largely attributed to the $5.7 billion Terns charge and high tax rate. This has left some investors concerned about the company's profitability, with a trailing net margin of 4.8%, significantly lower than last year's 25.8%. Despite this, management believes that heavy reinvestment today will eventually expand margins in the future.

The bullish view on Merck is that the company can offset future Keytruda pressure through an accelerating late-stage pipeline and recent launches that support faster revenue growth and healthier earnings over time. The oncology revenue is being spread across more products, with the Keytruda franchise, WELIREG, and new regimens all contributing to the 5% sales lift.

However, the bearish view on Merck is that heavy dependence on a few blockbuster drugs and aggressive deal making could leave earnings and margins exposed once exclusivity fades. The recent acquisition charge has validated some of these concerns, with investors questioning whether newer launches can carry the load when Keytruda eventually loses exclusivity.